ANI Pharma (ANIP) Misses Q4 EPS by 20c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to ANI Pharma (ANIP) Misses Q4 EPS by 20c

ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; Strong Foundation in Place to Drive Sustainable Growth

March 15, 2022 6:50 AM EDT

-- Fourth quarter net revenues of $60.9 million; net loss of $24.1 million and diluted loss per share of $1.72 --

-- Fourth quarter adjusted non-GAAP EBITDA of $16.2 million and adjusted non-GAAP diluted earnings per share of $0.54 --

-- Full year 2021 revenues of $216.1 million; net loss of $42.6 million and adjusted non-GAAP EBITDA of $64.8 million --

-- Launched Purified Cortrophin Gel for the treatment of certain chronic autoimmune disorders --

-- Experienced Rare Disease leadership and team in place to drive successful commercial launch of... More